| 1 | Intensification Approaches and Treatment Sequencing in Metastatic Castration-resistant Prostate Cancer: A Systematic Review | 2.1 | 34 | Citations (PDF) |
| 2 | Recent and Future Developments in the Use of Poly (ADP-ribose) Polymerase Inhibitors for Prostate Cancer | 5.8 | 9 | Citations (PDF) |
| 3 | A CT-based deep learning-driven tool for automatic liver tumor detection and delineation in patients with cancer | 6.6 | 21 | Citations (PDF) |
| 4 | Practical Guidance on Establishing a Molecular Testing Pathway for Alterations in Homologous Recombination Repair Genes in Clinical Practice for Patients with Metastatic Prostate Cancer | 5.8 | 20 | Citations (PDF) |
| 5 | Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial | 16.9 | 94 | Citations (PDF) |
| 6 | Marital Status, Living Arrangement, and Survival among Individuals with Advanced Prostate Cancer in the International Registry for Men with Advanced Prostate Cancer | 1.1 | 3 | Citations (PDF) |
| 7 | Chemotherapy in hormono-naïve prostate cancer 2024, , | | 0 | Citations (PDF) |
| 8 | Case report: Exceptional and durable response to Radium-223 and suspension of androgen deprivation therapy in a metastatic castration-resistant prostate cancer patient | 2.6 | 2 | Citations (PDF) |
| 9 | Reply to Anwar R. Padhani, Frederic LeCouvet, Giuseppe Petralia, and Dow-Mu Koh’s Letter to the Editor re: Alonso Garcia-Ruiz, Carlos Macarro, Francesca Zacchi, et al. Whole-body Magnetic Resonance Imaging as a Treatment Response Biomarker in Castration resistant Prostate Cancer with Bone Metastases: The iPROMET Clinical Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.02.016 | 2.1 | 2 | Citations (PDF) |
| 10 | RNASEH2B loss and PARP inhibition in advanced prostate cancer | 10.6 | 9 | Citations (PDF) |
| 11 | Metastatic hormone-naïve prostate cancer: a distinct biological entity | 10.4 | 8 | Citations (PDF) |
| 12 | Cyclophilin D plays a critical role in the survival of senescent cells | 7.3 | 30 | Citations (PDF) |
| 13 | Moving Precision Oncology for Advanced Prostate Cancer from Theory to Practice | 3.5 | 2 | Citations (PDF) |
| 14 | Detection of
BRCA1
,
BRCA2
, and
ATM
Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound | 6.8 | 77 | Citations (PDF) |
| 15 | Predictive Genomic Biomarkers of Hormonal Therapy Versus Chemotherapy Benefit in Metastatic Castration-resistant Prostate Cancer | 2.1 | 33 | Citations (PDF) |
| 16 | Pan-cancer Analysis of Homologous Recombination Repair–associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score | 6.8 | 80 | Citations (PDF) |
| 17 | Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib) | 6.8 | 102 | Citations (PDF) |
| 18 | Preclinical
In Vivo
Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification | 3.8 | 101 | Citations (PDF) |
| 19 | Clinical implications of homologous recombination repair mutations in prostate cancer | 2.1 | 8 | Citations (PDF) |
| 20 | Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors | 2.1 | 111 | Citations (PDF) |
| 21 | Characterizing CDK12-Mutated Prostate Cancers | 6.8 | 81 | Citations (PDF) |
| 22 | Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer | 3.3 | 32 | Citations (PDF) |
| 23 | A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors | 8.7 | 98 | Citations (PDF) |
| 24 | Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians | 2.1 | 40 | Citations (PDF) |
| 25 | Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer | 4.9 | 55 | Citations (PDF) |
| 26 | Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial | 25.1 | 142 | Citations (PDF) |
| 27 | Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients | 3.8 | 15 | Citations (PDF) |
| 28 | CD38 in Advanced Prostate Cancers | 2.1 | 38 | Citations (PDF) |
| 29 | Quantitative and Qualitative Analysis of Blood-based Liquid Biopsies to Inform Clinical Decision-making in Prostate Cancer | 2.1 | 83 | Citations (PDF) |
| 30 | Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA | 2.1 | 59 | Citations (PDF) |
| 31 | Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial | 27.4 | 601 | Citations (PDF) |
| 32 | Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer | 34.5 | 735 | Citations (PDF) |
| 33 | The future of bladder cancer therapy: Optimizing the inhibition of the fibroblast growth factor receptor | 9.5 | 26 | Citations (PDF) |
| 34 | First-in-Human Study of AT13148, a Dual ROCK-AKT Inhibitor in Patients with Solid Tumors | 6.8 | 67 | Citations (PDF) |
| 35 | Olaparib for Metastatic Castration-Resistant Prostate Cancer | 34.5 | 2,157 | Citations (PDF) |
| 36 | Genomics of lethal prostate cancer at diagnosis and castration resistance | 10.6 | 286 | Citations (PDF) |
| 37 | Managing Nonmetastatic Castration-resistant Prostate Cancer | 2.1 | 149 | Citations (PDF) |
| 38 | Genomic correlates of clinical outcome in advanced prostate cancer | 7.5 | 1,327 | Citations (PDF) |
| 39 | Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer | 2.1 | 75 | Citations (PDF) |
| 40 | Targeting DNA Repair Defects for Precision Medicine in Prostate Cancer | 4.2 | 19 | Citations (PDF) |
| 41 | BRCA2 and Other DDR Genes in Prostate Cancer | 3.8 | 87 | Citations (PDF) |
| 42 | Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency | 2.1 | 76 | Citations (PDF) |
| 43 | RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer | 6.8 | 59 | Citations (PDF) |
| 44 | Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study | 2.1 | 115 | Citations (PDF) |
| 45 | Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey | 3.5 | 20 | Citations (PDF) |
| 46 | Multiparametric Magnetic Resonance Imaging of Prostate Cancer Bone Disease | 6.8 | 51 | Citations (PDF) |
| 47 | Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer | 10.6 | 186 | Citations (PDF) |
| 48 | Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer | 2.6 | 41 | Citations (PDF) |
| 49 | SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity | 6.8 | 133 | Citations (PDF) |
| 50 | Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts | 9.9 | 87 | Citations (PDF) |
| 51 | A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) | 9.9 | 748 | Citations (PDF) |
| 52 | Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers | 5.8 | 37 | Citations (PDF) |
| 53 | Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition | 25.1 | 409 | Citations (PDF) |
| 54 | Effect on Overall Survival of Locoregional Treatment in a Cohort of De Novo Metastatic Prostate Cancer Patients: A Single Institution Retrospective Analysis From the Royal Marsden Hospital | 2.3 | 18 | Citations (PDF) |
| 55 | Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification | 6.8 | 36 | Citations (PDF) |
| 56 | A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors | 6.8 | 139 | Citations (PDF) |
| 57 | Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone | 9.9 | 25 | Citations (PDF) |
| 58 | Phenotypic diversity of circulating tumour cells in patients with metastatic castration‐resistant prostate cancer | 3.2 | 59 | Citations (PDF) |
| 59 | DNA Repair in Prostate Cancer: Biology and Clinical Implications | 2.1 | 217 | Citations (PDF) |
| 60 | Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study | 8.7 | 96 | Citations (PDF) |
| 61 | Interrogating the Cancer Genome to Deliver More Precise Cancer Care | 4.4 | 3 | Citations (PDF) |
| 62 | Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer | 34.5 | 1,583 | Citations (PDF) |
| 63 | Volume of Bone Metastasis Assessed with Whole-Body Diffusion-weighted Imaging Is Associated with Overall Survival in Metastatic Castration-resistant Prostate Cancer | 8.7 | 58 | Citations (PDF) |
| 64 | Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses | 2.3 | 38 | Citations (PDF) |
| 65 | An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib | 3.2 | 126 | Citations (PDF) |
| 66 | Biomarkers for Metastatic Castration-resistant Prostate Cancer (mCRPC): Yes or No? Predictive and Response Biomarkers Towards Precision Medicine in mCRPC | 3.5 | 1 | Citations (PDF) |
| 67 | A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies | 5.5 | 59 | Citations (PDF) |
| 68 | Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer | 2.1 | 135 | Citations (PDF) |
| 69 | Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer | 2.1 | 68 | Citations (PDF) |
| 70 | Interrogating the Cancer Genome to Deliver More Precise Cancer Care | 4.4 | 0 | Citations (PDF) |
| 71 | Integrative Clinical Genomics of Advanced Prostate CancerCell, 2015, 161, 1215-1228 | 33.6 | 3,307 | Citations (PDF) |
| 72 | Sequencing of agents in castration-resistant prostate cancer | 27.4 | 146 | Citations (PDF) |
| 73 | Switching and withdrawing hormonal agents for castration-resistant prostate cancer | 10.0 | 67 | Citations (PDF) |
| 74 | PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate | 2.1 | 243 | Citations (PDF) |
| 75 | Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration | 6.8 | 179 | Citations (PDF) |
| 76 | Baseline neutrophil–lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use | 9.9 | 184 | Citations (PDF) |
| 77 | DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer | 34.5 | 2,097 | Citations (PDF) |
| 78 | A Joint Model for the Kinetics of CTC Count and PSA Concentration During Treatment in Metastatic Castration‐Resistant Prostate Cancer | 2.7 | 24 | Citations (PDF) |
| 79 | Molecular Characterization and Clinical Utility of Circulating Tumor Cells in the Treatment of Prostate Cancer | 4.4 | 17 | Citations (PDF) |
| 80 | A first-in-human study of the anti-α5β1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors | 2.1 | 34 | Citations (PDF) |
| 81 | Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail | 5.5 | 38 | Citations (PDF) |
| 82 | External Validation of a Prognostic Model Predicting Overall Survival in Metastatic Castrate-resistant Prostate Cancer Patients Treated with Abiraterone | 2.1 | 25 | Citations (PDF) |
| 83 | Novel drugs targeting the androgen receptor pathway in prostate cancer | 6.9 | 33 | Citations (PDF) |
| 84 | The promise of circulating tumor cell analysis in cancer management | 8.1 | 48 | Citations (PDF) |
| 85 | Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone | 5.5 | 55 | Citations (PDF) |
| 86 | Appraising iniparib, the PARP inhibitor that never was—what must we learn? | 70.7 | 95 | Citations (PDF) |
| 87 | Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor | 4.9 | 325 | Citations (PDF) |
| 88 | Phase IB Dose-Escalation Study of the Akt Inhibitor Gdc-0068 with Docetaxel (D) or Modified Folfox6 (F) in Patients (PTS) with Advanced Solid Tumors | 9.9 | 0 | Citations (PDF) |
| 89 | The Clinical Utility of a Change in the Royal Marsden Hospital Prognostic Score (RMHPS) in Patients (PTS) Prior to Phase I Clinical Trial Therapy | 9.9 | 0 | Citations (PDF) |
| 90 | Opportunities and Pitfalls of Targeted Therapeutic Combinations in Solid Tumors | 4.4 | 0 | Citations (PDF) |
| 91 | Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer | 25.1 | 3 | Citations (PDF) |
| 92 | Therapy-induced senescence in prostate cancer: mechanisms, therapeutic strategies, and clinical implications | 2.3 | 10 | Citations (PDF) |
| 93 | Clinically feasible liver tumour cell size measurement through histology-informed in vivo diffusion MRI | 4.5 | 1 | Citations (PDF) |
| 94 | Combination therapy overcomes secondary PARPi resistance in ATM-deficient prostate cancer | 6.5 | 3 | Citations (PDF) |
| 95 | Expert practical recommendations for optimising tumour and germline testing of homologous recombination repair gene mutations in metastatic prostate cancer | 0.2 | 0 | Citations (PDF) |
| 96 | Classification tree phenotypes for early treatment-limiting toxicity after androgen receptor pathway inhibitor initiation in metastatic hormone-sensitive prostate cancer from the IRONMAN registry. | 16.9 | 0 | Citations (PDF) |
